BPC-157 vs Ovagen
Extensively Studied vs Moderate Research
compatible Both support GI health; different mechanisms.
Molecular Data
BPC-157 Ovagen
Weight 1,419.53 Da 375 Da
Half-life <30 minutes Not established
Chain 15 amino acids 3 amino acids
Type Pentadecapeptide Tripeptide bioregulator
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Ovagen
01 Reduces long-term liver fibrosis
02 Protects GI mucosal layer
03 Defense against antibiotic damage
04 Protection from environmental toxins
05 May protect against chemotherapy GI effects
06 Tissue-specific targeting via PEPT transporters
07 Direct DNA regulation
08 Part of comprehensive anti-aging protocols
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Ovagen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Ovagen
Generally well-tolerated
Minimal side effects reported
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Active liver emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
BPC-157 Ovagen
Status Extensively Studied Moderate Research
References 6 studies 3 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.